Philadelphia Trust Company’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$513K Sell
3,684
-962
-21% -$135K 0.04% 158
2025
Q4
$570K Buy
4,646
+2,456
+112% +$298K 0.04% 150
2025
Q3
$243K Buy
+2,190
New +$249K 0.02% 224
2025
Q1
Sell
-85,437
Closed -$7.89M 248
2024
Q4
$7.89M Sell
85,437
-745
-0.9% -$67.1K 0.58% 44
2024
Q3
$7.22M Buy
86,182
+9,565
+12% +$730K 0.52% 48
2024
Q2
$5.26M Sell
76,617
-6,673
-8% -$445K 0.41% 57
2024
Q1
$6.1M Sell
83,290
-551
-0.7% -$42.4K 0.49% 55
2023
Q4
$6.79M Sell
83,841
-1,400
-2% -$109K 0.64% 49
2023
Q3
$6.39M Buy
85,241
+831
+1% +$63.9K 0.66% 48
2023
Q2
$6.5M Sell
84,410
-2,485
-3% -$198K 0.62% 50
2023
Q1
$7.21M Sell
86,895
-5,225
-6% -$433K 0.73% 39
2022
Q4
$7.91M Sell
92,120
-13,210
-13% -$1.05M 0.85% 29
2022
Q3
$6.5M Sell
105,330
-5,775
-5% -$364K 0.73% 37
2022
Q2
$6.87M Sell
111,105
-755
-0.7% -$46.7K 0.71% 39
2022
Q1
$6.65M Buy
111,860
+45,845
+69% +$2.93M 0.52% 50
2021
Q4
$4.79M Buy
66,015
+915
+1% +$63K 0.35% 60
2021
Q3
$4.55M Buy
65,100
+50,050
+333% +$3.52M 0.34% 63
2021
Q2
$1.04M Sell
15,050
-1,463
-9% -$97.7K 0.07% 132
2021
Q1
$1.07M Sell
16,513
-110
-0.7% -$7.09K 0.08% 129
2020
Q4
$968K Buy
16,623
+42
+0.3% +$2.53K 0.08% 121
2020
Q3
$1.05M Sell
16,581
-433
-3% -$30K 0.1% 107
2020
Q2
$1.31M Buy
17,014
+262
+2% +$20.1K 0.14% 89
2020
Q1
$1.25M Sell
16,752
-2,310
-12% -$160K 0.16% 79
2019
Q4
$1.24M Sell
19,062
-3,355
-15% -$218K 0.11% 103
2019
Q3
$1.42M Sell
22,417
-2,125
-9% -$139K 0.13% 98
2019
Q2
$1.66M Sell
24,542
-630
-3% -$41.4K 0.15% 102
2019
Q1
$1.64M Buy
25,172
+1,262
+5% +$83.9K 0.14% 92
2018
Q4
$1.5M Buy
23,910
+175
+0.7% +$12.2K 0.16% 88
2018
Q3
$1.83M Buy
23,735
+220
+0.9% +$16.6K 0.15% 91
2018
Q2
$1.67M Sell
23,515
-1,320
-5% -$93.2K 0.15% 90
2018
Q1
$1.87M Buy
24,835
+2,855
+13% +$227K 0.16% 93
2017
Q4
$1.57M Buy
21,980
+2,709
+14% +$206K 0.12% 104
2017
Q3
$1.56M Buy
19,271
+3,081
+19% +$236K 0.13% 105
2017
Q2
$1.15M Buy
16,190
+1,652
+11% +$110K 0.1% 115
2017
Q1
$987K Buy
14,538
+240
+2% +$16.9K 0.08% 122
2016
Q4
$1.02M Sell
14,298
-1,533
-10% -$114K 0.08% 126
2016
Q3
$1.25M Buy
15,831
+670
+4% +$54.4K 0.11% 109
2016
Q2
$1.26M Sell
15,161
-5,235
-26% -$465K 0.11% 108
2016
Q1
$1.87M Buy
20,396
+5,248
+35% +$473K 0.16% 79
2015
Q4
$1.6M Sell
15,148
-13,560
-47% -$1.41M 0.13% 87
2015
Q3
$2.82M Buy
28,708
+17,537
+157% +$1.95M 0.25% 69
2015
Q2
$95.4K Sell
11,171
-173,906
-94% -$19M 0.35% 69
2015
Q1
$18.2M Buy
185,077
+48,985
+36% +$4.97M 1.38% 30
2014
Q4
$12.8M Sell
136,092
-43,425
-24% -$4.49M 1.03% 39
2014
Q3
$19.1M Sell
179,517
-26,378
-13% -$2.58M 1.19% 42
2014
Q2
$17.1M Buy
205,895
+195,645
+1,909% +$15.2M 1.06% 42
2014
Q1
$726K Buy
+10,250
New +$804K 0.05% 118

Other funds holding GILD

Philadelphia Trust Company's GILD Position: Q1 2026 in Review

Philadelphia Trust Company reduced its Gilead Sciences (GILD) stake by 21% in Q1 2026, selling an estimated $135K and leaving 3,684 shares worth $513K. The position accounts for 0.04% of the portfolio, ranked #158.

Philadelphia Trust Company first reported a position in GILD in Q1 2014 and has held it in 47 quarters since. The position peaked at $19.1M in Q3 2014. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Philadelphia Trust Company held 3,684 shares of Gilead Sciences worth $513K as of Q1 2026.
  • Philadelphia Trust Company sold 962 Gilead Sciences shares in Q1 2026, an estimated $135K.
  • Gilead Sciences made up 0.04% of Philadelphia Trust Company's portfolio in Q1 2026, its #158 holding.
  • Philadelphia Trust Company first reported a position in Gilead Sciences in Q1 2014 and has held it in 47 quarters since.
  • Philadelphia Trust Company's Gilead Sciences position peaked at $19.1M in Q3 2014.
  • 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Philadelphia Trust Company's 13F filing for Q1 2026, filed 13 May 2026.